Fidaxomicin

C. diff Risk

None

Oral Bioavailability

None

Approximate Cost

$189.20/day

Spectrum Of Activity

Dosing

No dosage adjustment necessary (minimal systemic absorption)

No supplemental doses required for HD

C. difficile
200mg po BID x 10days

General Information

Acceptable Uses

First line therapy for first episode or recurrent CDAD

NOTE: NLPDP and Eastern Health Criteria for use differ

See Eastern Health CDAD Treatment Guidelines for more information

Common Usage

C. difficile colitis

Adverse Effects

  • ¬†GI disturbance

  • ¬†Cytopenias

  • ¬†Hypersensitivity: facial, tongue or throat swelling

Tablet/Capsule Strengths

SPECIAL AUTHORIZATION REQUIRED

Additional Information

EH Prescribing Restrictions
None

NLPDP Status
Special Authorization required
More Information

See Eastern Health CDAD treatment guidelines for therapy recommendations.

Pharmacology

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Urine penetration: None

Lung penetration: None

CSF penetration: None

Biliary penetration: None